Humacyte (NASDAQ:HUMA) Stock Rating Reaffirmed by Benchmark

Humacyte (NASDAQ:HUMAGet Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Benchmark in a research note issued on Thursday, Benzinga reports. They currently have a $15.00 target price on the stock. Benchmark’s target price would indicate a potential upside of 161.78% from the company’s previous close.

Several other research analysts have also recently issued reports on the company. BTIG Research raised their price objective on Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a report on Monday, September 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Humacyte presently has a consensus rating of “Buy” and an average price target of $9.80.

View Our Latest Stock Analysis on Humacyte

Humacyte Trading Up 3.2 %

Shares of Humacyte stock opened at $5.73 on Thursday. The firm’s 50 day simple moving average is $6.08 and its two-hundred day simple moving average is $5.79. The firm has a market capitalization of $683.88 million, a price-to-earnings ratio of -4.56 and a beta of 1.45. Humacyte has a 12-month low of $1.96 and a 12-month high of $9.97. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMAGet Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Analysts predict that Humacyte will post -1.09 EPS for the current year.

Insider Transactions at Humacyte

In related news, Director Kathleen Sebelius sold 5,182 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the transaction, the director now directly owns 40,276 shares in the company, valued at $217,490.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the transaction, the director now owns 40,276 shares in the company, valued at $217,490.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Laura E. Niklason sold 157,704 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $5.42, for a total value of $854,755.68. Following the transaction, the chief executive officer now owns 3,519,558 shares in the company, valued at $19,076,004.36. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,084,153 shares of company stock valued at $6,869,996 in the last 90 days. 11.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Humacyte

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. lifted its holdings in Humacyte by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock valued at $62,000 after purchasing an additional 7,897 shares in the last quarter. Hartline Investment Corp acquired a new position in shares of Humacyte during the 1st quarter worth about $70,000. Private Advisor Group LLC lifted its stake in Humacyte by 232.7% in the 1st quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock valued at $988,000 after buying an additional 222,144 shares in the last quarter. Capstone Investment Advisors LLC acquired a new stake in Humacyte in the 1st quarter worth about $972,000. Finally, Vanguard Group Inc. increased its stake in Humacyte by 28.7% during the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after buying an additional 896,415 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

(Get Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Featured Stories

Analyst Recommendations for Humacyte (NASDAQ:HUMA)

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.